银诺医药(2591.HK)今日首日招股，截至目前，券商一共为其借出逾93.66亿港元孖展，以公开发售集资额6828万港元计，相当于超额认购逾136倍。 银诺医药是自港交所落实IPO改革方案以来的首只新股，拟发行3655.64万股H股，10%在港作公开发售，不设回拨机制，但可重新分配至最多15%。另外，交易设有15%发售量调整权及15%超额配股权。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.